IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ

被引:168
作者
Beatty, GL [1 ]
Paterson, Y [1 ]
机构
[1] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA
关键词
D O I
10.4049/jimmunol.166.4.2276
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The importance of CD4(+) T cells in the induction of an optimal antitumor immune response has largely been attributed to their ability to provide costimulatory signals for the priming of MHC class I-restricted CD8(+) CTL However, many reports have demonstrated a requirement for CD4(+) T cells in the effector phase of tumor rejection indicating a greater responsibility for CD4(+) T cells in controlling tumor outgrowth. We demonstrate here a critical role for CD4(+) T cells in restraining initial tumor development through the inhibition of tumor angiogenesis, Using a tumor variant that is unresponsive to IFN-gamma, we show that tumor responsiveness to IFN-gamma is necessary for IFN-gamma -dependent inhibition of tumor angiogenesis by CD4(+) T cells. These studies reveal a pivotal role for CD4(+) T cells in controlling early tumor development through inhibition of tumor angiogenesis.
引用
收藏
页码:2276 / 2282
页数:7
相关论文
共 60 条
[11]   PROTECTION AGAINST SYNGENEIC LYMPHOMA BY A LONG-LIVED CYTO-TOXIC T-CELL CLONE [J].
DAILEY, MO ;
PILLEMER, E ;
WEISSMAN, IL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (17) :5384-5387
[12]   THE POSSIBLE ROLE OF ANGIOGENESIS IN THE METASTATIC POTENTIAL OF HUMAN-MELANOMA - CLINICOPATHOLOGICAL ASPECTS [J].
DENIJN, M ;
RUITER, DJ .
MELANOMA RESEARCH, 1993, 3 (01) :5-14
[13]   ENHANCED IN-VIVO GROWTH AND RESISTANCE TO REJECTION OF TUMOR-CELLS EXPRESSING DOMINANT-NEGATIVE IFN-GAMMA RECEPTORS [J].
DIGHE, AS ;
RICHARDS, E ;
OLD, LJ ;
SCHREIBER, RD .
IMMUNITY, 1994, 1 (06) :447-456
[14]   Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a Fas-independent pathway for specific tumor cell lysis [J].
Echchakir, H ;
Bagot, M ;
Dorothée, G ;
Martinvalet, D ;
Le Gouvello, S ;
Boumsell, L ;
Chouaib, S ;
Bensussan, A ;
Mami-Chouaib, F .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (01) :74-80
[15]   Antiangiogenic gene therapy [J].
Folkman, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9064-9066
[16]  
FUJIWARA H, 1984, J IMMUNOL, V133, P1671
[17]  
Gee MS, 1999, CANCER RES, V59, P4882
[18]  
GRAHAM CH, 1994, AM J PATHOL, V145, P510
[19]  
GREENBERG PD, 1991, ADV IMMUNOL, V49, P281
[20]   ERADICATION OF DISSEMINATED MURINE LEUKEMIA BY CHEMO-IMMUNOTHERAPY WITH CYCLOPHOSPHAMIDE AND ADOPTIVELY TRANSFERRED IMMUNE SYNGENEIC LYMPHOCYTES-LYT-1+2- [J].
GREENBERG, PD ;
CHEEVER, MA ;
FEFER, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 154 (03) :952-963